{"filings":[{"id":1056521,"accession_number":"0002007919-26-000033","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-06-15T20:06:58+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts Inhibrx BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma.","No filing review issues identified; PDUFA goal date set for April 14, 2027.","If approved, ozekibart would be first FDA-approved systemic therapy for this indication.","Pivotal ChonDRAgon trial showed 52% risk reduction in disease progression/death (HR 0.479; p<0.0001).","Median PFS 5.52 months for ozekibart vs 2.66 months for placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":833437,"accession_number":"0002007919-26-000030","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-06-03T20:02:12+00:00","items":["5.07"],"status":"ready","headline":"Inhibrx shareholders elect Forsyth and Manhard as directors, ratify BDO USA","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 11,541,232 shares (79% of outstanding) present at June 3, 2026 annual meeting.","Douglas G. Forsyth elected Class II director with 7,608,469 votes for, 1,463,474 withheld.","Kimberly Manhard elected Class II director with 9,035,097 votes for, 36,846 withheld.","Ratification of BDO USA as auditor passed: 11,510,478 for, 30,347 against, 407 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442436,"accession_number":"0002007919-26-000028","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-05-14T20:04:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx Q1 2026 net loss $33.4M; cash $161.7M; ozekibart BLA submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.4M ($2.15/sh) vs $43.3M ($2.80/sh) YoY; R&D expense $25.2M down from $36.9M.","Cash $161.7M at Mar 31, 2026 vs $124.2M at Dec 31, 2025; $75M loan amendment from Oxford.","BLA submitted to FDA for ozekibart in conventional chondrosarcoma; discuss accelerated pathways for CRC and Ewing sarcoma.","INBRX-106 Phase 2 HNSCC updated interim data in May 2026; PFS results expected Q4 2026.","Debt increased to $175M; other expense $2.5M from higher interest on new $75M principal."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12762,"accession_number":"0002007919-26-000020","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-05-11T20:02:50+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inhibrx: INBRX-106 + pembro achieves 44% ORR vs 21.4% in HNSCC Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR 44.0% (11/25) for combo vs 21.4% (6/28) for pembro alone; absolute increase 22.6%.","Three complete responses in combo arm vs zero in control; deeper tumor reductions overall.","Up to 15-fold increase in CD8+ and CD4+ T-cell proliferation in combo arm (vs up to 2.5-fold).","No treatment-related deaths; most common AEs: rash, diarrhea, fatigue, infusion reactions.","Phase 3 HexAgon start Q3 2026; perioperative NSCLC study later this quarter; metastatic NSCLC in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97171,"accession_number":"0002007919-26-000010","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inhibrx reports 20% ORR with ozekibart combo in late-line CRC; BLA submitted for chondrosarcoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 20% in 45 evaluable patients vs historical 1-6% for standard of care; responses durable >6 months.","Median PFS 5.5 months; 42% progression-free at 6 months; DCR 87%.","Manageable safety, mostly Grade 1-2 diarrhea, fatigue, nausea; no significant liver toxicity despite 68% with liver metastases.","Plans to meet FDA in H2 2026 for first-line registrational trial; accelerate pathways for 4th-line CRC and refractory Ewing sarcoma.","BLA submitted to FDA for ozekibart in conventional chondrosarcoma in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111727,"accession_number":"0002007919-26-000007","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.","Cash $124.2M at Dec 31, 2025; received $75M gross proceeds from Oxford Finance on Mar 18, 2026.","R&D expense $113M (down 44% YoY); G&A $23.3M (down 82% YoY) due to lower clinical costs and prior-year transaction expenses.","ozekibart BLA submission for chondrosarcoma expected early Q2 2026; PFS data for CRC expansion Q2 2026.","INBRX-106: interim ORR data from Phase 2/3 HNSCC trial expected Q2 2026; PFS data at ESMO Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111726,"accession_number":"0002007919-26-000002","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibrx publishes updated corporate presentation on investor website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted February 23, 2026 under the Investors tab of www.inhibrx.com.","Filing includes only presentation disclaimer; substantive pipeline and financial details not accessible in this report.","Company routinely updates this presentation for conferences and meetings; no specific material changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128356,"accession_number":"0002007919-25-000097","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inhibrx provides INBRX-106 and ozekibart trial updates; Ewing sarcoma FDA meeting planned for H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INBRX-106 HNSCC Phase 2/3: 46 of 60 patients enrolled; completion expected Q1 2026.","NSCLC Phase 1/2 trial completed enrollment of 34 patients in Nov 2025; data immature.","Ozekibart colorectal cancer expansion cohort enrolled 44 patients; PFS data mature Q2 2026.","Ewing sarcoma trial enrollment expected Q2 2026; FDA meeting for accelerated approval planned H2 2026 if trends continue.","No efficacy data released; management cautions datasets lack maturity for conclusions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128355,"accession_number":"0002007919-25-000094","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx reports Q3 net loss $35.3M; ozekibart meets primary endpoint in chondrosarcoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.3M ($2.28 per share) vs $43.9M ($2.84) in Q3 2024; R&D expense down to $28.5M.","Cash and equivalents $153.1M at Sept 30, 2025, down from $186.6M at June 30, 2025.","Ozekibart (INBRX-109) met primary endpoint in registrational chondrosarcoma trial, showing statistically significant PFS improvement.","Plan to submit BLA to FDA in Q2 2026; expansion cohorts in colorectal cancer and Ewing sarcoma show high response rates.","$100M debt outstanding; interest expense of $3.2M in Q3 2025."],"consensus_eps_estimate":-1.7524,"consensus_eps_actual":-6.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":1300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128354,"accession_number":"0002007919-25-000089","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ozekibart meets primary endpoint in chondrosarcoma; BLA submission planned Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ChonDRAgon study achieved primary endpoint: 52% reduction in risk of progression or death (HR=0.479; p<0.0001); median PFS 5.52 vs 2.66 months.","Disease control rate 54% (ozekibart) vs 27.5% (placebo); benefit consistent across IDH subgroups.","CRC expansion cohort (n=26 evaluable): 23% ORR, 92% disease control rate in heavily pretreated patients.","Ewing sarcoma expansion (n=25 evaluable): 64% ORR, 92% disease control rate; typical standard of care ORR 15-30%.","One fatal hepatotoxicity event early in study; risk mitigated by excluding severe liver impairment and close monitoring; overall hepatic AEs 11.8% vs 4.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145159,"accession_number":"0002007919-25-000083","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx reports Q2 net loss of $28.7M; cash $186.6M; key trial data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.7M ($1.85/share) vs net income of $1.9B in Q2 2024 due to $2B gain from 101 transaction.","Revenue $1.3M (up from $0.1M); R&D $22.3M (-67% YoY); G&A $6.4M (-93% YoY).","Cash and equivalents $186.6M at June 30, down from $216.5M at March 31.","Ozekibart (INBRX-109) Phase 2 chondrosarcoma trial fully enrolled; results expected by late Oct 2025.","Initial Phase 2 data for INBRX-106 in head/neck cancer + pembrolizumab expected in Q4 2025."],"consensus_eps_estimate":-2.8162,"consensus_eps_actual":-4.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1300000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163561,"accession_number":"0002007919-25-000063","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inhibrx stockholders elect two Class I directors, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jon Faiz Kayyem, Ph.D. elected with 8,077,611 votes for, 31,060 withheld (3,384,613 broker non-votes).","Kristiina Vuori, M.D., Ph.D. elected with 6,494,317 votes for, 1,614,354 withheld (3,384,613 broker non-votes).","Ratification of BDO USA as auditor passed with 11,463,328 for, 2,918 against, 27,038 abstained.","Quorum of 11,493,284 shares (79% of eligible) was present at the May 28, 2025 virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163560,"accession_number":"0002007919-25-000057","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx Q1 net loss $43.3M; cash $216.5M after $100M loan; data readouts expected in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $43.3M ($2.80/share) vs $78.7M ($5.77/share) in Q1 2024.","Cash $216.5M at March 31, 2025, up from $152.6M after $100M loan from Oxford Finance in Jan 2025.","INBRX-109 registration-enabling Phase 2 data for chondrosarcoma expected Q3 2025; CRC cohort data also Q3 2025.","INBRX-106 Phase 2/3 data for HNSCC with Keytruda expected Q4 2025; interim NSCLC data Q4 2025.","R&D expenses fell to $36.9M from $63.9M due to spin-off of INBRX-101 program in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163559,"accession_number":"0002007919-25-000028","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inhibrx promotes David Matly to President; CSO Eckelman resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Matly appointed President effective April 1, 2025, adding to his role as EVP, Chief Commercial and Business Development Officer.","Mark Lappe remains CEO and Chair but no longer holds President title; Matly's base salary increased to $601,670.","Matly granted 50,000 stock options vesting over four years under the company's equity plan.","Brendan P. Eckelman resigned as EVP, Chief Scientific Officer effective March 31, 2025, to found a new private biotech.","Company accelerated vesting of 50,000 of Eckelman's outstanding options and extended post-termination exercise period to October 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181468,"accession_number":"0002007919-25-000020","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx reports FY2024 net income of $1.7B driven by spin-off gain; secures $100M loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $1.7B (EPS $114.01 basic) vs net loss of $241.4M in FY2023; gain from Sanofi INBRX-101 sale.","Cash of $152.6M at Dec 31, 2024; after $100M Oxford loan in Jan 2025, $230.5M as of Feb 28, 2025.","R&D expense $203.7M (FY2024) vs $191.6M; includes $25.9M stock option acceleration from spin-off.","G&A expense $127.9M (FY2024) vs $29.4M; includes $68.1M spin-off costs and $15.2M option acceleration.","Ozekibart Phase 1 CRC data: 1 CR, 3 PRs, median PFS 7.85 mo; expansion cohort enrolling up to 50 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181467,"accession_number":"0002007919-25-000007","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inhibrx reports ozekibart Phase 1 CRC data: 40% ORR, median PFS 7.85 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1 CR, 3 PR among 10 evaluable patients; median PFS of 7.85 months.","Durable disease control ≥180 days observed in 46.2% of treated patients.","Grade ≥3 TEAEs in 30.8% of patients; most AEs mild to moderate.","Expansion cohort enrolling up to 50 patients, data expected Q3 2025.","Two PRs occurred in patients who had failed prior FOLFIRI-based therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181466,"accession_number":"0002007919-25-000003","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Inhibrx secures $150M loan facility from Oxford Finance; $100M funded upfront","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan and Security Agreement with Oxford Finance for up to $150M term loan; $100M funded on Jan 13, 2025.","Remaining $50M available at Inhibrx's request and Lenders' sole discretion.","Interest-only payments through Feb 2028; maturity Jan 1, 2030; rate = 1M SOFR + 5.61% (floor 4.34%).","Issued warrants for 140,741 shares at $14.21/exercise price, representing 2% of initial $100M tranche.","Proceeds provide strategic flexibility ahead of expected data readouts for INBRX-109 and INBRX-106 programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198259,"accession_number":"0002007919-24-000060","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibrx Biosciences Q3 net loss $43.9M ($2.84/shr); cash $196.3M; trial readouts in next 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $196.3M as of Sep 30, 2024, down from $226.9M at June 30, 2024.","Net loss of $43.9M ($2.84 per share) vs $51.8M ($4.39 per share) in Q3 2023.","R&D expense $38.9M, up slightly from $38.1M, driven by expansion of Phase 2 trial for ozekibart (INBRX-109) and INBRX-106 trials.","No outstanding third-party debt post-spin-off; other income of $2.9M from interest on cash balances.","Company expects data readouts for its two ongoing clinical programs within the next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":117.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198258,"accession_number":"0002007919-24-000054","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inhibrx wins trade secrets trial against I-Mab; jury rejects all misappropriation claims","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found in favor of Inhibrx, rejecting I-Mab's allegations of misappropriation of trade secrets.","Lawsuit filed March 1, 2022, claimed Inhibrx and CSO Brendan Eckelman improperly used I-Mab's proprietary info.","Certain matters remain before the court; Inhibrx notes potential appeals or further proceedings.","The verdict removes a significant legal overhang for Inhibrx.","Inhibrx announced the jury verdict on November 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214381,"accession_number":"0002007919-24-000031","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inhibrx Biosciences reports $1.9B net income in Q2 2024 after separation from former parent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $1.9 billion for Q2 2024, compared to net loss of $47.1 million in Q2 2023","Cash and cash equivalents $226.9M as of June 30, 2024, down from $255.4M at May 30 separation","Separation from Inhibrx, Inc. completed May 30: INBRX-101 transferred to Sanofi for ~$2.2B","Stockholders received $30 cash per share, one $5 CVR, and one Inhibrx Biosciences share per four former parent shares"],"consensus_eps_estimate":null,"consensus_eps_actual":122.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233595,"accession_number":"0002007919-24-000016","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibrx posts updated corporate presentation; no material details in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated corporate presentation on its website on June 17, 2024.","No specific pipeline, financial, or milestone updates are visible from the filed excerpt.","Presentation attached as Exhibit 99.1; full content not included in this 8-K text.","Routine update without quantitative or event-driven disclosures for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233594,"accession_number":"0001104659-24-066645","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","5.01","5.02","8.01","9.01"],"status":"ready","headline":"Inhibrx Biosciences completes spin-off from RemainCo, lists 14.5M shares outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed spin-off on May 29, 2024; 92% of Inhibrx Biosciences shares distributed to RemainCo shareholders at 1:4 ratio.","As of May 30, 2024, 14,475,904 shares of common stock outstanding post-distribution.","Issued warrants for up to 991,849 shares at $0.0001 exercise price, no expiration; also issued 1,838 shares to Oxford Finance.","Entered registration rights agreement requiring filing of resale registration statement within 10 business days.","Entered employment agreements with CEO Lappe ($695,250 base), CFO Eckelman ($535,600), and CAO Deck ($460,100) with 12-month severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233593,"accession_number":"0001104659-24-065140","cik":2007919,"company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibrx Biosciences spin-off registration effective; distribution May 29, merger with Sanofi May 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registration statement on Form 10 declared effective by SEC on May 24, 2024.","Distribution of 92% of Inhibrx Biosciences shares to RemainCo holders at 1:4 ratio; effective May 29.","RemainCo merger with Sanofi expected to close May 30, subject to conditions.","When-issued trading under INXBV from May 28; regular-way under INXB from May 30; then INBX from May 31."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1503796513.252427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}